Viridian Therapeutics, Inc. , a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent ...

a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics ...

a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics ...

Amgen isn't resting on its laurels, though, particularly with other potential rivals circling, such as Viridian Therapeutics and its anti-IGF-1R antibody veligrotug that needs five infusions and ...

Viridian Therapeutics’s stock has jumped after a Phase III trial of veligrotug met all endpoints and was well tolerated in patients with chronic thyroid eye disease (TED). The THRIVE-2 ...

Lonigutamab (VB-421) is a subcutaneously delivered anti-IGF-1R that is currently being evaluated in a phase 1 study for thyroid eye disease. It is estimated to be a market opportunity worth over ...

OD values were used to estimate the extent of antibody binding detected. Analysis revealed that IGF-1R and TSHR shared homologous sequences with major capsid proteins of the Papillomaviridae ...

This reprogramming unlocks robust anti-tumor immunity in cancer models, even against tumor types that have traditionally resisted checkpoint blockade immunotherapies." The antibody has received ...

LX-101, a Novel, Clinical Stage, Payload-Bearing Targeted Therapy Directed to the Insulin-Like Growth Factor Receptor (IGF-1R), Demonstrates Potent Anti-Tumor Activity in Ewing Sarcoma Animal ...